{
    "eid": "2-s2.0-85107395405",
    "title": "Fecal microbiota transplantation for irritable bowel syndrome: An intervention for the 21stcentury",
    "cover-date": "2021-06-14",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Gastroenterology",
            "@code": "2715",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Butyric acid",
        "Enteroendocrine cells",
        "Etiology",
        "Microbiota",
        "Short-chain fatty acids",
        "Superdonor",
        "Therapy"
    ],
    "authors": [
        "Magdy El-Salhy",
        "Tanisa Patcharatrakul",
        "Sutep Gonlachanvit"
    ],
    "citedby-count": 10,
    "ref-count": 111,
    "ref-list": [
        "The epidemiology of irritable bowel syndrome",
        "Recent developments in the pathophysiology of irritable bowel syndrome",
        "FMT in IBS: how cautious should we be?",
        "Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options",
        "Overlapping of irritable bowel syndrome with erosive esophagitis and the performance of Rome criteria in diagnosing IBS in a clinical setting",
        "Introduction to the human gut microbiota",
        "The Microbiome and Irritable Bowel Syndrome - A Review on the Pathophysiology, Current Research and Future Therapy",
        "A comprehensive repertoire of prokaryotic species identified in human beings",
        "Evolution of mammals and their gut microbes",
        "The Super-Donor Phenomenon in Fecal Microbiota Transplantation",
        "Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study",
        "Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery",
        "Fecal microbiota transplantation for managing irritable bowel syndrome",
        "Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD",
        "Dysbiosis in Functional Bowel Disorders",
        "Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome",
        "Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis",
        "Should we standardize the 1,700-year-old fecal microbiota transplantation?",
        "Clostridium difficile Infection and Fecal Microbiota Transplant",
        "Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis",
        "A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group",
        "Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial",
        "Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study",
        "Faecal microbiota transplantation for diarrhoeapredominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial",
        "The Effect of Allogenic Versus Autologous Fecal Microbiota Transfer on Symptoms, Visceral Perception and Fecal and Mucosal Microbiota in Irritable Bowel Syndrome: A Randomized Controlled Study",
        "Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome",
        "Fecal Microbiota Transplantation Reduces Symptoms in Some Patients With Irritable Bowel Syndrome With Predominant Abdominal Bloating: Short- and Long-term Results From a Placebo-Controlled Randomized Trial",
        "Letter: faecal microbiota transplantation for IBS",
        "Letter: faecal microbiota transplantation for irritable bowel syndrome-room for improvement",
        "Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial",
        "Exploring the Efficacy of Pooled Stools in Fecal Microbiota Transplantation for Microbiota-Associated Chronic Diseases",
        "Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial",
        "The interaction between smoking, alcohol and the gut microbiome",
        "Smoking cessation alters intestinal microbiota: insights from quantitative investigations on human fecal samples using FISH",
        "Cohort profile: Finnish Health and Early Life Microbiota (HELMi) longitudinal birth cohort",
        "Pilot Study to Determine the Gut Microbiota of Hong Kong Infants Fed with Breast-milk And/or Infant Formula (P11-101-19)",
        "Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by caesarean section",
        "The mode of delivery affects the diversity and colonization pattern of the gut microbiota during the first year of infants' life: a systematic review",
        "Antibiotics as deep modulators of gut microbiota: between good and evil",
        "Antibiotics and the gut microbiota",
        "Extensive impact of non-antibiotic drugs on human gut bacteria",
        "Fecal Microbiota Transplantation: Screening and Selection to Choose the Optimal Donor",
        "The Effects of Dietary Pattern during Intensified Training on Stool Microbiota of Elite Race Walkers",
        "Exercise influence on the microbiome-gut-brain axis",
        "Exercise Training Modulates Gut Microbiota Profile and Improves Endotoxemia",
        "Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)?",
        "Is fecal microbiota transplantation the answer for irritable bowel syndrome?",
        "Diet and effects of diet management on quality of life and symptoms in patients with irritable bowel syndrome",
        "Part 2: Treatments for Chronic Gastrointestinal Disease and Gut Dysbiosis",
        "Assessment of faecal microbial transfer in irritable bowel syndrome with severe bloating",
        "Factors Affecting Gastrointestinal Microbiome Development in Neonates",
        "Effect of intestinal preparation on the efficacy and safety of fecal microbiota transplantation treatment",
        "Efficacy of different faecal microbiota transplantation protocols for Clostridium difficile infection: A systematic review and meta-analysis",
        "Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS)",
        "Changes in fecal short-chain fatty acids following fecal microbiota transplantation in patients with irritable bowel syndrome",
        "Responses to faecal microbiota transplantation in female and male patients with irritable bowel syndrome",
        "Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug",
        "Systematic Review: Adverse Events of Fecal Microbiota Transplantation",
        "The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications",
        "Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant",
        "Fecal Microbiota Transplantation for Dysbiosis - Predictable Risks",
        "Faecal microbial transplantation in IBS: ready for prime time?",
        "FMT in IBS: a call for caution",
        "Long-Term Efficacy and Safety of Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides difficile Infection",
        "Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome: A systematic review and meta-analysis",
        "Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones",
        "Irritable bowel syndrome: diagnosis and pathogenesis",
        "Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment",
        "Irritable bowel syndrome: the role of gut neuroendocrine peptides",
        "Is irritable bowel syndrome an organic disorder?",
        "Gut hormones: emerging role in immune activation and inflammation",
        "5-Hydroxytryptamine (serotonin) in the gastrointestinal tract",
        "The serotonin signaling system: from basic understanding to drug development for functional GI disorders",
        "Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease",
        "Review article: intestinal serotonin signalling in irritable bowel syndrome",
        "Occurrence and distribution of 5-hydroxytryptamine (enteramine) in the living organism",
        "Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception",
        "Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism",
        "Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease",
        "Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome",
        "Enteroendocrine, Musashi 1 and neurogenin 3 cells in the large intestine of Thai and Norwegian patients with irritable bowel syndrome",
        "Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease",
        "Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis",
        "Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome",
        "Clostridium ramosum regulates enterochromaffin cell development and serotonin release",
        "Immunocytochemical identification of polypeptide YY (PYY) cells in the human gastrointestinal tract",
        "Possible role of peptide YY (PYY) in the pathophysiology of irritable bowel syndrome (IBS)",
        "Multiple Y receptors mediate pancreatic polypeptide responses in mouse colon mucosa",
        "Neuropeptide Y, Y1, Y2 and Y4 receptors mediate Y agonist responses in isolated human colon mucosa",
        "Structural characterization of Y1 and Y2 receptors for neuropeptide Y and peptide YY by affinity cross-linking",
        "Evidence for further heterogeneity of the receptors for neuropeptide-Y and peptide-YY in tumor cell lines derived from neural crest",
        "Peptide YY receptor in submucosal and myenteric plexus synaptosomes of canine small intestine",
        "Localization and characterization of neuropeptide Y binding sites in porcine and human colon",
        "Expression of the human neuropeptide tyrosine Y1 receptor",
        "Molecular characterization of a second mouse pancreatic polypeptide receptor and its inactivated human homologue",
        "Cloning and characterization of a novel receptor to pancreatic polypeptide, a member of the neuropeptide Y receptor family",
        "Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors",
        "Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of intracisternal CRF-induced inhibition of gastric acid secretion in rats",
        "The regulation of veratridine-stimulated electrogenic ion transport in mouse colon by neuropeptide Y (NPY), Y1 and Y2 receptors",
        "Functional consequences of neuropeptide Y Y 2 receptor knockout and Y2 antagonism in mouse and human colonic tissues",
        "Butyrate modulates oxidative stress in the colonic mucosa of healthy humans",
        "Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats",
        "Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents",
        "Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine",
        "Review article: the role of butyrate on colonic function",
        "Beneficial effect of butyrateproducing Lachnospiraceae on stress-induced visceral hypersensitivity in rats",
        "Butyrate promotes visceral hypersensitivity in an IBS-like model via enteric glial cell-derived nerve growth factor",
        "Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome",
        "The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats",
        "Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome",
        "Fecal Fermentation in Irritable Bowel Syndrome: Influence of Dietary Restriction of Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bergen",
            "@id": "60029622",
            "affilname": "Universitetet i Bergen",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60029622",
            "affiliation-country": "Norway"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Helse Fonna"
    ]
}